Astellas Hits Sagent, Strides With Adenoscan IP Suit

Law360, Washington (June 21, 2011, 5:39 PM EDT) -- Astellas Pharma US LLC and affiliate Item Development AB hit Sagent Pharmaceuticals Inc. and Strides Arcolab Ltd. with a lawsuit in New Jersey federal court on Tuesday for allegedly violating a patent for the pharmacologic stress agent Adenoscan.

Sagent has filed an Abbreviated New Drug Application with the the U.S. Food and Drug Administration seeking approval to make a generic version of Adenoscan, according to Astellas.

The patent-in-suit is U.S. Patent No. 5,731,296, “a selective vasodilation by continuous adenosine infusion” that is set to expire in...
To view the full article, register now.